Alcon Agrees to Acquire STAAR Surgical

How will the acquisition affect Alcon’s earnings per share (EPS) guidance and revenue forecasts? What is the acquisition price and how does it compare to STA*R Surgical’s current market valuation? What is the projected impact of the acquisition on Alcon’s cash flow and debt levels? What synergies does Alcon expect to realize from integrating STA*R Surgical's product portfolio? What integration challenges might arise in combining the two companies’ R&D pipelines and manufacturing operations? Will the deal be funded in cash, stock, or a combination, and what are the immediate financing implications for Alcon? When is the expected closing date and are there any regulatory approvals or antitrust concerns that could delay the transaction? How will the merger impact Alcon’s competitive position relative to other ophthalmic device players such as Johnson & Johnson and Bausch + Lomb? How might the market’s perception of the deal influence Alcon’s stock price volatility in the short term? Will there be any changes to Alcon’s dividend policy or share repurchase program post‑acquisition?